Drug Trial Radar · NCT03412292
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Jan 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 1, 2018
Primary completion
Nov 1, 2022
Study completion Dec 1, 2022
Sponsor
- Lead sponsor
- Maxinovel Pty., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose-escalation phase I trial to evaluate the safety and tolerability of MAX-40279 in subjects with acute myelogenous leukemia(AML).
Conditions
- Acute Myelogenous Leukemia (AML)
Interventions
MAX-40279Drug
MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S. MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light. MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: 8 weeks
- Maximum tolerated dose (MTD)Time frame: 4 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
St Vincent's Hospital Sydney Limited
Darlinghurst, New South Wales, Australia · Recruiting
Western NSW Local Health District
Dubbo, New South Wales, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.